» Articles » PMID: 15851848

Differential Loss of Synaptic Proteins in Alzheimer's Disease: Implications for Synaptic Dysfunction

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2005 Apr 27
PMID 15851848
Citations 174
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of our research was to determine synaptic protein levels in brain specimens from AD subjects and age-matched control subjects. Further, to determine whether presynaptic or postsynaptic compartments of neurons are preferentially affected in AD patients, we studied 3 presynaptic vesicle proteins (synaptotagmin, synaptophysin, and Rab 3A), 2 synaptic membrane proteins (Gap 43 and synaptobrevin), and 2 postsynaptic proteins (neurogranin and synaptopodin) in specimens from AD and age-matched control brains. Two brain regions--the frontal and parietal cortices--were assessed for protein levels by immunoblotting analysis. We found a loss of both presynaptic vesicle proteins and postsynaptic proteins in all brain specimens from AD patients compared to those from age-matched control subjects. Further, we found that the loss of synaptic proteins was more severe in the frontal cortex brain specimens than in the parietal cortex brain specimens from the AD subjects compared to those from the control subjects, suggesting that the frontal brain may be critical for synaptic function in AD. Using immunohistochemistry techniques, we also determined the distribution pattern of all synaptic proteins in both the frontal and parietal cortices brain specimens from control subjects. Of the 7 synaptic proteins studied, the presynaptic proteins synaptophysin and rab 3A and the postsynaptic protein synaptopodin were the most down-regulated. Our study suggests that postsynaptic proteins and presynaptic proteins are important for synaptic function and may be related to cognitive impairments in AD.

Citing Articles

Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment.

Gonzalez A, Edwards L, Thomas K, Weigand A, Bordyug M, Brenner E Neuropsychology. 2025; 39(3):248-258.

PMID: 40063372 PMC: 11904934. DOI: 10.1037/neu0000981.


Neurodegeneration in the cortical sulcus is a feature of chronic traumatic encephalopathy and associated with repetitive head impacts.

Nicks R, Shah A, Stathas S, Kirsch D, Horowitz S, Saltiel N Acta Neuropathol. 2024; 148(1):79.

PMID: 39643767 PMC: 11624223. DOI: 10.1007/s00401-024-02833-8.


Pharmacological inhibition of PLK2 kinase activity mitigates cognitive decline but aggravates APP pathology in a sex-dependent manner in APP/PS1 mouse model of Alzheimer's disease.

Martinez-Drudis L, Berard M, Musiol D, Rivest S, Oueslati A Heliyon. 2024; 10(20):e39571.

PMID: 39498012 PMC: 11532864. DOI: 10.1016/j.heliyon.2024.e39571.


Exosomes in the Diagnosis of Neuropsychiatric Diseases: A Review.

Wu S, Shang X, Guo M, Su L, Wang J Biology (Basel). 2024; 13(6).

PMID: 38927267 PMC: 11200774. DOI: 10.3390/biology13060387.


Alzheimer's disease and its treatment-yesterday, today, and tomorrow.

Kim A, Al Jerdi S, MacDonald R, Triggle C Front Pharmacol. 2024; 15:1399121.

PMID: 38868666 PMC: 11167451. DOI: 10.3389/fphar.2024.1399121.